Overview

* Medpace Q2 2025 revenue up 14.2% to $603.3 mln, beating analyst expectations

* Clinical contract research organization's GAAP net income for Q2 rises to $90.3 mln, with net income margin of 15.0%

* Company repurchased 1.75 mln shares for a total of $518.5 mln in Q2 2025

Outlook

* Medpace ( MEDP ) forecasts 2025 revenue between $2.420 bln and $2.520 bln

* Company expects full-year GAAP net income of $405 mln to $428 mln

* Medpace ( MEDP ) sees 2025 diluted EPS ranging from $13.76 to $14.53

Result Drivers

* BACKLOG CONVERSION - Revenue growth represents a backlog conversion rate of 21.2%

* NET NEW BUSINESS - Increase in net new business awards to $620.5 mln contributed to revenue growth

* COST INCREASES - Higher direct costs and SG&A expenses impacted net income margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $603.31 $538.80

Revenue mln mln (9

Analysts

)

Q2 Net $90.26

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Medpace Holdings Inc ( MEDP ) is $300.00, about 4% below its July 18 closing price of $311.87

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)